Alcon raises STAAR Surgical acquisition price to $30.75 per share from $28.00

STAAR SURGICAL CO

Merger consideration increased to $30.75/share in cash, up from $28.00/share (approx. 9.8% increase).
Amendment treats RSUs and PSUs as Alcon equity awards; PSUs deemed earned at 100% of target.
Amendment eliminates 280G gross-up and related tax indemnification arrangements.
Deal requires stockholder approval and regulatory clearances; proxy statement filed September 16, 2025.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

STAAR SURGICAL CO amended Amendment No. 2 with Alcon Research, LLC and Rascasse Merger Sub, Inc. valued at $30.75 per share (effective 2025-12-09).

Action: amendment
Agreement: merger
Counterparty: Alcon Research, LLC and Rascasse Merger Sub, Inc.
Value: $30.75 per share
Effective: 2025-12-09

Exact text from the filing

On December 9, 2025, STAAR Surgical Company (the “Company”) entered into Amendment No. 2 (the “Amendment”) to the Agreement and Plan of Merger, dated August 4, 2025 (as amended, the “Amended Merger Agreement”), with Alcon Research, LLC (“Alcon”) and Rascasse Merger Sub, Inc. (“Merger Sub”).

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

STAAR SURGICAL CO filing history →

Source: SEC EDGAR

accession 0001193125-25-311982

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.